← Leaderboards
Tanya Parish
Access To Advanced Health Institute
$17,248,999
Attributed
$17,463,661
Total exposure
15
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2009–25$2.5M$1.9M$1.3M$625K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,463,661 · 15
By mechanism
R01$12,189,447 · 6
R21$1,429,175 · 3
N01$1,410,030 · 1
R56$888,000 · 2
N02$864,806 · 1
P30$501,278 · 2
Top collaborators
- Steven Michael Johnson2 shared
- Joshua O Odingo1 shared
Others in their field
Top investigators on “Tuberculosis”
- Judith S. Currier · University Of California Los Angeles$301,722,065
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$297,204,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$267,912,117
- Lawrence Corey · Fred Hutchinson Cancer Center$255,939,398
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$200,192,298
- Sharon A Nachman · Johns Hopkins University$194,852,226
Research focus
TuberculosisMycobacterium TuberculosisLeadNovel TherapeuticsPathogenFutureAntibioticsBacteriaInfectionCessation Of LifeCellsPharmaceutical PreparationsDrug DevelopmentDrug DiscoveryIn VitroSeriesAnti-Bacterial AgentsBiologicalBaseCommunicable DiseasesDrug ResistanceIn VivoResistanceProperty
Grant awards (37)
New anti-tubercular agents targeting intracellular bacteria$931,143
R01 · FY2025 · AI · contact PI
Targeting protein secretion in Mycobacterium tuberculosis$861,105
R01 · FY2025 · AI · contact PI
New anti-tubercular agents targeting intracellular bacteria$935,324
R01 · FY2024 · AI · contact PI
Targeting protein secretion in Mycobacterium tuberculosis$902,701
R01 · FY2024 · AI · contact PI
Basic Science Core$133,558
P30 · FY2024 · AI · contact PI
High content, high throughput, diversity screen for novel anti-tubercular agents targeting intracellular bacteria$246,125
R21 · FY2023 · AI · contact PI
Basic Science Core$144,017
P30 · FY2023 · AI · contact PI
Developing triazolopyrimidines as novel anti-tubercular agents$492,250
R56 · FY2022 · AI · contact PI
The role of Esx-3 in mediating drug resistance$464,998
R01 · FY2022 · AI · contact PI
High content, high throughput, diversity screen for novel anti-tubercular agents targeting intracellular bacteria$295,350
R21 · FY2022 · AI · contact PI
Basic Science Core$223,703
P30 · FY2022 · AI · contact PI
The role of Esx-3 in mediating drug resistance$464,998
R01 · FY2021 · AI · contact PI
Identifying GroEL inhibitors with activity against replicating and non-replicating Mycobacterium tuberculosis$83,150
R03 · FY2021 · AI
Identifying GroEL inhibitors with activity against replicating and non-replicating Mycobacterium tuberculosis$97,775
R03 · FY2020 · AI
High Content Screening of Mycobacterium Tuberculosis$649,245
R01 · FY2019 · AI · contact PI
The role of Esx-3 in mediating drug resistance$464,998
R01 · FY2019 · AI · contact PI
High content screening of Mycobacterium tuberculosis$631,092
R01 · FY2018 · AI · contact PI
The role of Esx-3 in mediating drug resistance$435,250
R01 · FY2018 · AI · contact PI
High content screening of Mycobacterium tuberculosis$646,203
R01 · FY2017 · AI · contact PI
TASK A27: In Vitro Characterization Of Antimicrobial Activity$638,080
N01 · FY2017 · AI · contact PI
Chemical probes of vulnerable pathways in antibiotic-resistant pathogens$714,724
R01 · FY2016 · AI · contact PI
Phenoxyalkylimidazoles for use against persistent and replicating M. tuberculosis$207,000
R21 · FY2016 · AI · contact PI
Task A19: In Vitro Assessment of Anti-Microbial Activity$746,950
N01 · FY2015 · AI · contact PI
Chemical probes of vulnerable pathways in antibiotic-resistant pathogens$744,764
R01 · FY2015 · AI · contact PI
High throughput assays to detect inhibition of a key M. tuberculosis protease$387,500
R01 · FY2015 · AI · contact PI
Phenoxyalkylimidazoles for use against persistent and replicating M. tuberculosis$248,400
R21 · FY2015 · AI
Chemical probes of vulnerable pathways in antibiotic-resistant pathogens$750,021
R01 · FY2014 · AI · contact PI
Task A14: In Vitro Assessment of Antimicrobial Activity for TB$575,850
N02 · FY2014 · AI · contact PI
High throughput assays to detect inhibition of a key M. tuberculosis protease$387,500
R01 · FY2014 · AI · contact PI
Task A13: Cultivating currently uncultivable bacterial pathogens$288,956
N02 · FY2014 · AI · contact PI
Chemical probes of vulnerable pathways in antibiotic-resistant pathogens$705,796
R01 · FY2013 · AI · contact PI
High throughput assays to detect inhibition of a key M. tuberculosis protease$364,250
R01 · FY2013 · AI · contact PI
Chemical probes of vulnerable pathways in antibiotic-resistant pathogens$747,835
R01 · FY2012 · AI · contact PI
High throughput assays to detect inhibition of a key M. tuberculosis protease$395,750
R56 · FY2011 · AI · contact PI
In Vitro Assessments for Antimicrobial Activity$25,000
N01 · FY2011 · AI · contact PI
The Role of Lipoarabinomannan in Mycobacterium tuberculosis$196,500
R21 · FY2010 · AI · contact PI
The Role of Lipoarabinomannan in Mycobacterium tuberculosis$235,800
R21 · FY2009 · AI · contact PI